| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 6.97 | 0.27 (+4.03%) | 2.56 - 7.53 | 221.0 thousand (Below Avg) |
Market data as of 4:00PM 05/23/13. Quotes are delayed by at least 15 min.
| Open | 6.61 |
|---|---|
| Previous Close | 6.70 |
| Day's Range | 6.54 - 7.00 |
| Market Cap | 598.0M |
| Avg Volume (10 Day) | 384.1K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.71 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Cadence Pharmaceuticals To Present At Three Investment Conferences During The Month Of May 2013
PR Newswire - Wednesday 05/08/2013 4:00 PM ET
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
PR Newswire - Thursday 05/02/2013 4:00 PM ET
Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss First Quarter 2013 Financial Results On May 2, 2013
PR Newswire - Thursday 04/25/2013 4:00 PM ET
| CADX | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 170.19% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.60 | |
| LT Debt/Equity | 0.55 | |
| Earnings Yield | -- | |
| Price/Sales | 8.74 |
| Company | Last | Change |
|---|---|---|
| Ambit Biosciences Corp | 7.17 | +6.22% |
| Dendreon Corp | 3.91 | -1.01% |
| ChemoCentryx Inc | 13.94 | +3.11% |
| Idenix Pharmaceuticals Inc | 4.19 | +0.96% |
| Exact Sciences Corp | 10.54 | -0.38% |
Data is delayed by at least 15 min.